FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025206987> ?p ?o ?g. }

• W3025206987 abstract "External beam radiotherapy is a treatment option for clinically localised prostate cancer; however, some 15% of patients will undergo treatment failure within 5 years. The objective was to compare the Cancer of the Prostate Risk Assessment (CAPRA) score (based on the clinical-pathological findings) and the sub-types of minimal residual disease (MRD) (based on the biological properties of the cancer cells) risk classifications to predict biochemical failure (BF) after external beam radiotherapy.Clinical-pathological findings were obtained from the prostate biopsy to determine the CAPRA score and used to define low-, intermediate- and high-risk patients. Blood and bone marrow were obtained 3 months after radiotherapy; circulating prostate cells (CPCs) and micro-metastasis were detected using immunocytochemistry with anti-prostate specific antigen. CPCs and micro-metastasis were classified as positive if at least one cell was detected in the sample. Three subgroups were formed Group A (MRD negative), Group B (micro-metastasis positive, CPC negative) and Group C (CPC positive)Patients were followed up for 10 years or until biochemical failure. Biochemical failure free survival (BFFS) curves were constructed using Kaplan-Meier (observed), a flexible parameter model (predicted survival) and the restricted mean survival time (RMST) was calculated for each sub-group.309 men participated with a median follow-up of 8 years. The risk of biochemical failure increased proportionally with increasing CAPRA score, hazard ratio 1.18 for intermediate and 1.69 for high risk patients. After 10 years, the percentage BFFS and RMST to failure were 74%, 49%, 16% and 9, 7 and 6 years, respectively. The agreement between observed and predicted BFFS was acceptable (Harrell´s C 0.62). The BFFS curves for MRD were different and not proportional, survival curves for men MRD negative and only micro-metastasis were similar up to 5 years, and then there was increasing failure in the micro-metastasis only group. After 10 years, the percentage BFFS and RMST to failure were 95%, 59%, 28% and 10, 9 and 6 years, respectively. The CAPRA score failed to distinguish between Groups A and B, one third of high risk Group C had low risk CAPRA scores. The agreement between observed and predicted BFFS was very good (Harrell´s C 0.92). Minimal residual disease hazard ratios were Group B 1.84 and Group C 4.51.The MRD prognostic classification is based on the biological characteristics of the tumour cell-microenvironment interaction, to give three groups, MRD negative, only bone marrow micro-metastasis and CPC positive prostate cancer. Differing from the CAPRA score classification the risk of treatment failure changes with time, differentiating between early and late treatment failures and incorporates the concept of dormancy. It proved to be superior to the CAPRA score in predicting biochemical failure and the results need to be confirmed in larger studies." @default.
• W3025206987 created "2020-05-21" @default.
• W3025206987 creator A5006306123 @default.
• W3025206987 creator A5010733521 @default.
• W3025206987 creator A5030131247 @default.
• W3025206987 creator A5031014315 @default.
• W3025206987 creator A5038840444 @default.
• W3025206987 creator A5051939215 @default.
• W3025206987 creator A5082843116 @default.
• W3025206987 date "2020-05-12" @default.
• W3025206987 modified "2023-10-18" @default.
• W3025206987 title "The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy" @default.
• W3025206987 cites W1194264668 @default.
• W3025206987 cites W1492336771 @default.
• W3025206987 cites W1970678392 @default.
• W3025206987 cites W1974950800 @default.
• W3025206987 cites W1974962780 @default.
• W3025206987 cites W1975348342 @default.
• W3025206987 cites W1984289109 @default.
• W3025206987 cites W2026037933 @default.
• W3025206987 cites W2026113581 @default.
• W3025206987 cites W2026419161 @default.
• W3025206987 cites W2035936829 @default.
• W3025206987 cites W2045030989 @default.
• W3025206987 cites W2072013249 @default.
• W3025206987 cites W2076989190 @default.
• W3025206987 cites W2083043726 @default.
• W3025206987 cites W2092876014 @default.
• W3025206987 cites W2093703180 @default.
• W3025206987 cites W2093867637 @default.
• W3025206987 cites W2095621222 @default.
• W3025206987 cites W2144484686 @default.
• W3025206987 cites W2166339706 @default.
• W3025206987 cites W2167148167 @default.
• W3025206987 cites W2194569594 @default.
• W3025206987 cites W2276538843 @default.
• W3025206987 cites W2400734080 @default.
• W3025206987 cites W2493667027 @default.
• W3025206987 cites W2522266941 @default.
• W3025206987 cites W2522328871 @default.
• W3025206987 cites W2889190934 @default.
• W3025206987 cites W2906240986 @default.
• W3025206987 cites W2920212336 @default.
• W3025206987 cites W2948508821 @default.
• W3025206987 cites W2950653098 @default.
• W3025206987 cites W2992366037 @default.
• W3025206987 cites W39352419 @default.
• W3025206987 doi "https://doi.org/10.3332/ecancer.2020.1042" @default.
• W3025206987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7289617" @default.
• W3025206987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32565895" @default.
• W3025206987 hasPublicationYear "2020" @default.
• W3025206987 type Work @default.
• W3025206987 sameAs 3025206987 @default.
• W3025206987 citedByCount "1" @default.
• W3025206987 countsByYear W30252069872021 @default.
• W3025206987 crossrefType "journal-article" @default.
• W3025206987 hasAuthorship W3025206987A5006306123 @default.
• W3025206987 hasAuthorship W3025206987A5010733521 @default.
• W3025206987 hasAuthorship W3025206987A5030131247 @default.
• W3025206987 hasAuthorship W3025206987A5031014315 @default.
• W3025206987 hasAuthorship W3025206987A5038840444 @default.
• W3025206987 hasAuthorship W3025206987A5051939215 @default.
• W3025206987 hasAuthorship W3025206987A5082843116 @default.
• W3025206987 hasBestOaLocation W30252069871 @default.
• W3025206987 hasConcept C121608353 @default.
• W3025206987 hasConcept C126322002 @default.
• W3025206987 hasConcept C143998085 @default.
• W3025206987 hasConcept C207103383 @default.
• W3025206987 hasConcept C207886595 @default.
• W3025206987 hasConcept C2775908122 @default.
• W3025206987 hasConcept C2776235491 @default.
• W3025206987 hasConcept C2779013556 @default.
• W3025206987 hasConcept C2780192828 @default.
• W3025206987 hasConcept C44249647 @default.
• W3025206987 hasConcept C509974204 @default.
• W3025206987 hasConcept C71924100 @default.
• W3025206987 hasConceptScore W3025206987C121608353 @default.
• W3025206987 hasConceptScore W3025206987C126322002 @default.
• W3025206987 hasConceptScore W3025206987C143998085 @default.
• W3025206987 hasConceptScore W3025206987C207103383 @default.
• W3025206987 hasConceptScore W3025206987C207886595 @default.
• W3025206987 hasConceptScore W3025206987C2775908122 @default.
• W3025206987 hasConceptScore W3025206987C2776235491 @default.
• W3025206987 hasConceptScore W3025206987C2779013556 @default.
• W3025206987 hasConceptScore W3025206987C2780192828 @default.
• W3025206987 hasConceptScore W3025206987C44249647 @default.
• W3025206987 hasConceptScore W3025206987C509974204 @default.
• W3025206987 hasConceptScore W3025206987C71924100 @default.
• W3025206987 hasLocation W30252069871 @default.
• W3025206987 hasLocation W30252069872 @default.
• W3025206987 hasLocation W30252069873 @default.
• W3025206987 hasLocation W30252069874 @default.
• W3025206987 hasOpenAccess W3025206987 @default.
• W3025206987 hasPrimaryLocation W30252069871 @default.
• W3025206987 hasRelatedWork W10226643 @default.
• W3025206987 hasRelatedWork W1068400 @default.
• W3025206987 hasRelatedWork W12305472 @default.
• W3025206987 hasRelatedWork W12927781 @default.
• W3025206987 hasRelatedWork W13920211 @default.
• W3025206987 hasRelatedWork W1589844 @default.

• next